In dogs, anti-inflammatory therapy for MGD has been studied how extensively?

• A. It is well-studied in multiple trials
• B. It is minimally studied; one case report used tobramycin/dexamethasone for blepharitis/MGD
• C. It has not been documented
• D. It is standard therapy

Answer: (B)

Meibomian gland disease in dogs is not accompanied by a large body of evidence on anti-inflammatory treatment. In the canine literature, anti-inflammatory approaches for MGD are sparse, with only a single case report describing the use of topical tobramycin/dexamethasone for blepharitis associated with MGD. This means there isn’t extensive, multi-trial evidence to support routine or standard anti-inflammatory therapy in dogs with MGD. A case report can hint at potential benefit, but it doesn’t provide broad, generalizable data. Therefore, the statement that anti-inflammatory therapy has been minimally studied in dogs, with only one case report, best fits the current knowledge.